PREDiCT: Imaging Modalities for Oncology Drug Development

The progress of multimodal imaging techniques offers pharmaceutical companies the opportunity to fast-track evidence of drug response and therapeutic action. At the PREDiCT: Imaging Modalities for Oncology Drug Development Summit we will reveal the strategy behind the multimodal applications to understand how this information can determine clinical candidate success.

Join us in Boston with 60+ experts alongside organisations such as National Institute of Health, Genentech, MD Anderson Cancer Institute, Bristol Myers Squibb and more  and utilize industry insight behind the latest imaging modalities to monitor immune responses in a safe and non-invasive manner, enabling you to accelerate your oncology drug development with confidence.